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Abstract
Background: Participation in low-dose CT (LDCT) lung cancer screening offered in the trial context has been poor,
especially among smokers from socioeconomically deprived backgrounds; a group for whom the risk-benefit ratio is
improved due to their high risk of lung cancer. Attracting high risk participants is essential to the success and
equity of any future screening programme. This study will investigate whether the observed low and biased uptake
of screening can be improved using a targeted invitation strategy.
Methods/design: A randomised controlled trial design will be used to test whether targeted invitation materials
are effective at improving engagement with an offer of lung cancer screening for high risk candidates. Two
thousand patients aged 60–75 and recorded as a smoker within the last five years by their GP, will be identified
from primary care records and individually randomised to receive either intervention invitation materials (which
take a targeted, stepped and low burden approach to information provision prior to the appointment) or control
invitation materials. The primary outcome is uptake of a nurse-led ‘lung health check’ hospital appointment, during
which patients will be offered a spirometry test, an exhaled carbon monoxide (CO) reading, and an LDCT if eligible.
Initial data on demographics (i.e. age, sex, ethnicity, deprivation score) and smoking status will be collected in
primary care and analysed to explore differences between attenders and non-attenders with respect to invitation
group. Those who attend the lung health check will have further data on smoking collected during their
appointment (including pack-year history, nicotine dependence and confidence to quit). Secondary outcomes will
include willingness to be screened, uptake of LDCT and measures of informed decision-making to ensure the latter
is not compromised by either invitation strategy.
Discussion: If effective at improving informed uptake of screening and reducing bias in participation, this invitation
strategy could be adopted by local screening pilots or a national programme.
Trial registration: This study was registered with the ISRCTN (International Standard Registered Clinical/soCial
sTudy Number : ISRCTN21774741) on the 23rd September 2015 and the NIH ClinicalTrials.gov database
(NCT0255810) on the 22nd September 2015.
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Background
Worldwide, lung cancer kills more people than any
other cancer, explaining over one fifth of all cancer-
related mortality in the UK [1, 2]. Five-year survival is
poor at just 11.1 % for men and 15.0 % for women [3],
but prognosis improves significantly with earlier stage at
diagnosis. For example, five-year survival estimates in-
crease to 58–73 % when non-small cell lung cancer
(NSCLC) is diagnosed at the earliest stage (stage 1A) [4].
However, close to 70 % of patients are diagnosed with
advanced stage disease [5] with around 40 % presenting
via emergency admission [6] and almost a third dying
within 90 days of their diagnosis [7]. This is partly be-
cause detecting lung cancer early is challenging; early
symptoms are typically non-specific and they may not
even be manifest until the disease has progressed.
Data from the National Lung Screening Trial (NLST)
suggest that screening individuals at high risk of lung
cancer using low-dose computed tomography (LDCT)
scans is a potential early detection strategy. A 20 % rela-
tive risk reduction in lung cancer mortality and a 6.7 %
reduction for all-cause mortality was observed for pa-
tients aged 55–74 with a significant (≥30 pack-years)
and recent (within 15 years) smoking history, who
underwent three annual LDCT screens compared with
chest X-rays [8]. Subsequently, the US Preventive Ser-
vices Task Force (USPSTF) issued a grade B recommen-
dation for screening high risk adults; a preventive
service benefit now covered by Medicare and Medicaid
Services [9]. The case for implementation is building
within the UK where the National Screening Committee
is due to make a decision by 2016, following results ex-
pected from the European trials.
For any screening programme to be effective, it must
achieve a positive benefit-harm ratio, which in turn de-
pends upon attracting the high risk population. Increas-
ing the risk profile of participants has potential to
reduce avoidable invasive follow-up tests and the num-
ber needed to screen [10]. Indeed, NLST participants
categorised within the three highest quintiles of risk
benefitted from 88 % of screen-prevented deaths [11].
However, enrolment to screening offered within the trial
context has been extremely low, ranging from 0.2–4.6 %
of the total age-eligible population invited [12–15], and
biased toward former smokers, rather than current
smokers, and towards higher socioeconomic status (SES)
individuals [16, 17]. In the UK Lung Screening Trial
(UKLS), the proportion of individuals with a high lung
cancer risk score (using the Liverpool Lung Project
model) [18] increased with socioeconomic deprivation, yet
paradoxically response rates and subsequent clinic attend-
ance decreased [15]. This suggests that despite their high
risk, lower SES smokers are less likely to engage with an
offer of screening or see it through; a pervasive problem
observed across other screening programmes [19–21] and
healthcare services [22, 23].
It is essential that screening communication effectively
engages this group if lung cancer screening is to be an
equitable early detection strategy and attain adequate
uptake. To date, methods of recruitment into trials have
been heterogeneous, including mass-mailing, media ad-
vertisements, community outreach and GP enrolment
(e.g. [12, 14, 24]). Some initially invited all individuals in
the at-risk age group who were requested to complete
risk assessment measures and engage in further corres-
pondence to determine eligibility. Therefore, while we
know uptake is poorer among low SES smokers, it is dif-
ficult to ascertain the denominator of eligible individuals
invited to screening needed to reliably calculate levels of
uptake among high risk candidates. Furthermore, these
individuals have been invited to participate in a research
trial evaluating the clinical effectiveness of LDCT screen-
ing; an invitation that is likely to be interpreted very dif-
ferently from that for a lung cancer screening service.
To our knowledge, no study has taken a targeted ap-
proach to the design of invitation and information mate-
rials for (and in consultation with) high risk and ‘hard-
to-reach’ groups, nor attempted to test such a strategy in
the real-world context of a demonstration pilot lung
cancer screening service.
Aims
The primary aim of this study is evaluate the impact of a
targeted invitation strategy, compared with a control, on
uptake of ‘lung health check’ appointments overall and in
association with demographic and smoking characteristics.
The secondary aims of this study are to:
1. compare the demographic and smoking-related
characteristics of attenders versus non-attenders for
each invitation group, and with the overall invited
group,
2. explore informed decision-making outcomes by invi-
tation group to check that the information provided
to each is equally effective in facilitating a patient’s
ability to make an informed decision at the
appointment,
3. ascertain figures to help gauge uptake of a national
screening programme and inform the feasibility of
recruiting to a LDCT programme via primary care.
Methods/design
Study design
This study will use a two-arm, between-subjects,
individually-randomised controlled trial design to com-
pare uptake of lung cancer screening appointments be-
tween two groups allocated to receive either intervention
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or control invitation materials (see Fig. 1 for an overview
of participant flow through the trial).
Randomisation and allocation procedure
The individual unit of randomisation will be the patient.
A web-based randomisation programme has been con-
structed by an independent health research unit. This
will randomise patients at a ratio of 1:1 using permuted
blocks for each GP practice to ensure group allocation is
evenly balanced by practice. Patient identifiable details
will be concealed from the researcher carrying out the
randomisation assignment using a pseudo-anonymised
spreadsheet of eligible patient details exported securely
to the researcher from the GP practice. Patients will be
blind to their allocation and the research nature of the
study, which would undermine the primary outcome.
Setting and participants
Patients will be identified from primary care practices fall-
ing within three Clinical Commissioning Groups (CCGs):
Islington, Camden, and City and Hackney. These sites
were chosen because they have demographically diverse
patient populations. All patients will be invited by their
GP (by letter, including a clinic telephone helpline) to a
pre-scheduled ‘lung health check’ appointment with
two weeks’ notice. This will include an eligibility screen
(i.e. smoking and medical history), spirometry test, CO
reading, smoking cessation advice (for current smokers),
and for those eligible, a LDCT scan. The appointments
will be run by research nurses in outpatient clinics at a
central London tertiary referral hospital and an inner
London district general hospital (University College Hos-
pital and the Homerton University Hospital). Informed
consent will be taken by a research nurse at the beginning
of each lung health check appointment who will explain
Fig. 1 Trial flow diagram
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that the purpose of the pilot is to measure uptake and will
describe all other data being collected. Data on secondary
outcomes will not be collected for patients who do not
give consent.
Eligibility criteria
Inclusion criteria
Patients will be eligible for invitation if they are aged
60–75 years and have been recorded by their GP prac-
tice as a current smoker at any point since April 2010.
This threshold was chosen for two reasons: i) to identify
a group likely to have accrued the 30 pack-year history
conferring likely screening eligibility, and ii) to identify
predominantly current smokers as this is the group most
difficult to attract to screening.
Exclusion criteria
Patients will be excluded if they fulfil any of the follow-
ing criteria: have an active lung cancer diagnosis or me-
tastases, are on the palliative care register, have had a
recent CT thorax (≤12 months), lack capacity to con-
sent, or GP deems them unsuitable due to a comorbidity
contraindicative of screening for lung cancer or subse-
quent treatment.
Patient identification
The patient identification process will be supported dur-
ing an initial site visit by a member of the research team.
A standardised audit search will be imported and run by
practice administrators to extract details of eligible pa-
tients from GP record databases with ease and
consistency. The subsequent list of potentially eligible
patients will then be screened by GPs for patients they
deem unsuitable. To avoid contamination, only one eli-
gible patient per household will be enrolled.
Invitation procedure and adherence
The printing and mailing of materials will be carried out
via a secure third party company on behalf of each GP
practice. A researcher will support practice administra-
tors in uploading patient details, specifying the contents
of mail packs and assigning mailing dates using the
company’s electronic system. Allocation of appointments
will have been carried out by the research team at the
randomisation stage and input into the spreadsheet of
patient details so that these automatically populate the
invitation letters. This in-practice assistance will also
allow monitoring of adherence to the mailing protocol.
The mailing company’s activity will also be monitored
via checking of reported mailings to ensure they are be-
ing sent as instructed.
Control invitation materials
Table 1 provides a detailed breakdown of the content,
delivery and staging of information by invitation group.
Invitations in both arms will be from the patient’s own
GP. In the absence of ‘usual care’ invitation materials,
control invitations will mimic so far as possible the best
available materials and methods of established cancer
screening programmes. These comprise the following:
1. a pre-invitation letter notifying patients of the lung
health check service and an information booklet
mimicking so far as possible, those of existing
screening programmes,
2. an invitation letter with a pre-scheduled appoint-
ment plus the same information booklet that accom-
panied the pre-invitation letter,
3. a reminder re-invitation letter for those who miss
their appointment without cancelling (sent ≥4 weeks
following the missed appointment).
Intervention invitation approach: a targeted, stepped and
low burden invitation strategy
The intervention group will receive the same stages of
invitation materials as the control group. The two differ-
ences are: i) instead of the information booklet they will
receive a targeted leaflet (see Additional file 1), and ii)
the invitation and reminder letters will use indirect
phrasing to say that smokers and ex-smokers are being
invited. Together, these manipulations aim to deliver a
targeted, stepped and low-burden approach to informa-
tion provision prior to the appointment which, in
principle, would be practically feasible to implement on
a national scale. The group we are inviting will be far
from homogeneous but as it is not feasible to ascertain
each individual recipient’s characteristics prior to invita-
tion, we are attempting to provide the best ‘one size fits
all’ approach; inclusive enough to target a variety of dif-
ferent characteristics but also conservative, so as not to
unnecessarily deter one group at the expense of an-
other’s uptake. Materials have been tested during four
patient and public engagement sessions to ensure ac-
ceptability and comprehensibility and reviewed by our
multidisciplinary team (psychology, respiratory medicine,
radiology, smoking cessation, and primary care) and
community-academic partners from our qualitative
phase of work informing the invitation design ([25]; full
paper in prep).
Targeted component
This has been developed in response to what is known
about the characteristics and beliefs of the target group
from our own and existing research ([25–29]; full paper
in prep). It aims to minimise fear (particularly of an ex-
pected diagnosis at screening which actually has a low
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probability), fatalism, stigma and blame around lung
cancer by: i) emphasising a supportive and non-
judgemental service, ii) providing a lay explanation for
how early detection of lung cancer can work (using a
diagram to illustrate that the lung is a treatable organ
which need not be completely removed because early
treatment can be focussed within a lobe), iii) acknow-
ledging that the invited generation were previously not
as informed of the risks of smoking, iv) avoiding men-
tion of smoking, smoking cessation, and risk where pos-
sible at the invitation stage, v) emphasising the salience
for older adults, and vi) normalising the offer so as to
not implicate the reason for invitation as being that lung
cancer is suspected or that the recipient is being singled
out.
Stepped approach
This is guided by the Precaution Adoption Process
Model (PAPM) which depicts different stages of aware-
ness, engagement, decision-making and action for pre-
ventive health behaviours [30]. It is a useful framework
from which to hypothesise at what stage different types
of information could most effectively be communicated.
Given that the target group are likely to have no prior
awareness of lung cancer screening, the first contact is
designed to provide a positive introduction to the service
to engage them with the idea, without the pressure of
yet needing to decide whether to attend. Previous re-
search has shown that advance notification letters for
bowel cancer screening which include a low level of in-
formation successfully increase participation [31], par-
ticularly among men from socioeconomically deprived
backgrounds [32]. Written communication thereafter
contains cues to action intended to minimise non-
intentional factors that reduce participation (i.e. forget-
ting and procrastination). These include prescheduled
appointments, maps with travel information, and for those
who do not respond, reminder re-invitations, which have
previously been shown to be effective [31–34].
Low burden level of information prior to the appointment
The materials have a relatively low level of information
to promote consideration of the offer in a way that does
not overwhelm or overburden. This takes account of the
inherent challenges of communicating risk, uncertainty
and overdiagnosis [35, 36]; the scientific uncertainty of
estimates for lung cancer screening, its fast-moving evi-
dence base, the application of population risk modelling
to individual risk profiles, and new medical terminology
[37], difficulties comprehending this information which
are likely to be further exacerbated by the low levels of
health literacy and numeracy anticipated for the low SES
target group [38], and fear of lung cancer, which may in-
fluence receptivity to information and the ability to
Table 1 Information content and delivery by stage and invitation group
Delivery Content
(mode, messenger, recipients, time) Control arm Intervention arm
Pre-invitation Mailed 3–4 weeks prior to the appt
From GP (signature and letterhead)
All patients
Pre-invitation letter notifying the
patient of the lung health check service
Information booklet mimicking so far as
possible ‘the facts’ booklets for cancer
screening programmes
Identical pre-invitation letter to control
Targeted information leaflet introducing the
tests using a low burden approach including:
- content designed to reduce fear, fatalism, stigma
- explanation and diagram to show how early
treatment can work
- quotes from interview participants to
address stigma and highlight benefit
- emphasis on non-judgemental service
Invitation Mailed 2–3 weeks prior to the appt
From GP (signature and letterhead)
All patients
Letter inviting patients for a lung health
check including:
- statement that smokers and ex-smokers
are being invited
- pre-scheduled appointment
- contact details to cancel/rearrange/
further information
- information to help journey planning
(map/address/stations/buses)
Second copy of information booklet.
Control letter with one exception:
- statement changed to say that people
who have ever smoked are being invited
(rather than smokers and ex-smokers specifically)
Second copy of targeted information leaflet
Brief essential information on the reverse side
of the letter including details for requesting
free copy of information booklet
(phone or online)
Appointment Run by Research Nurse
All patients attending the appt
Information booklet
(same as mailed previously).
Nurse-led facilitation of informed
decision-making
Identical to control
Reminder Mailed ≥4 weeks after missed appt
From GP (signature and letterhead)
Patients who miss their appointment
without cancelling
Letter re-inviting the patient for a lung
health check appointment with similar
content to the invitation letter
Control letter with one exception:
- statement changed to say that people
who have ever smoked are being invited
(rather than smokers and ex-smokers specifically)
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weigh up information rationally [39]. Increased ambigu-
ity of information has been shown to confuse, raise sus-
picion and promote risk aversion among individuals
with low numeracy and low optimism [40, 41]. Further-
more, recipients’ first impressions of the amount of in-
formation could be important for information engagement
as perceived cognitive ease has been associated with more
positive appraisal of the information content [42].
All these factors considered, it seemed appropriate to
reduce the complexity of the information provided and
the decision required by the individual to that of decid-
ing whether to attend to discuss the tests. Free and easy
access to further information before the appointment
will be clearly signposted on invitation materials (for
both groups). Once at the appointment, the nurse can
provide a supported environment for the communica-
tion of complex information and can facilitate informed
decision-making. The patient can then choose whether
to have the tests the same day or a different day and the
nurse will ensure they do not feel under pressure to de-
cide either way.
Social marketing
The proposed approach, supporting evidence, and detailed
draft content, were communicated to a social marketing
team, who have used their expertise to creatively design
engaging materials tailored for the target audience. The
colour scheme and typography of the targeted leaflet is
based on the brand identities of businesses that target low
income customers. The images used are representative of
a diverse population and range of ages, so as to reflect and
engage the target audience. The leaflet uses a non-
authoritarian conversational tone and includes quotes
from our qualitative work to introduce a social presence
to the information ([25]; full paper in prep).
Methods of data collection and outcome measures
Demographics and smoking
Data on age, sex, ethnicity, smoking status and postcode
will be extracted from primary care records by practice
administrators for all patients identified as eligible and
invited. Postcodes will be converted to Index of Multiple
Deprivation (IMD) scores and ranks on site by a re-
searcher from a spreadsheet within which identifiable
data fields have been hidden. A pseudo-anonymised
spreadsheet containing all these data will then be com-
piled and exported to a researcher independent of the
identification process for randomisation and entry into
the study database. While developing this protocol, we
surveyed members of the public and patients about
accessing this data prior to consent and none inter-
viewed had any objections.
At the appointment, these data will be verified by a
nurse who will take informed consent for the collection
of any further data post-attendance. Further data collec-
tion will include information on attendees’ highest level
of education (as an additional measure of SES) and mea-
sures of smoking behaviour and history. These will in-
clude current smoking status (self-reported and CO
verified), usual number of cigarettes smoked daily, age
started smoking, pack-year history, use of other nicotine
and tobacco products (pipes, cigars, electronic cigarettes,
waterpipes, smokeless tobacco) nicotine dependence
(two item Heaviness of Smoking Index) [43] and quit
confidence within the next six months.
Primary outcome
Uptake of the lung health check appointments will be
recorded by the nurses running the lung health check
appointments prior to consent. It will be measured by
attendance because the outcome of interest is whether
participants can be adequately engaged to consider lung
cancer screening. The aim is to provide a realistic indica-
tion of uptake in a real-world clinical context. Recording
attendance is already standard practice in a clinical con-
text and knowing that participation is being recorded for
research purposes would introduce observer bias and
undermine the research question.
Secondary outcomes
To further explore interest and uptake of screening, will-
ingness to be screened will be used as a proxy measure
to gauge interest among those attending who are ineli-
gible for a LDCT scan, and uptake of LDCT scans will
be recorded among those eligible. Data on informed
decision-making (i.e. objective and subjective knowledge,
decisional conflict, decisional satisfaction) will also be
collected at the appointment using a paper question-
naire. Items have been adapted from existing studies and
measures, and low literacy scales have been chosen
where available [44–46]. These measures will allow us to
ensure the targeted invitation strategy does not com-
promise the ability of patients to make an informed de-
cision about screening at their appointment. Scores on
these measures will be compared by invitation group to
ensure intervention participants achieve either similar or
improved scores.
Sample size
The target sample size is 2000 patients. This is based on
an estimate that 35 % of patients in the control group
will attend, similar to initial uptake of colorectal cancer
screening (by FOBT) in London within the two most de-
prived IMD quintiles [47]. The aim is to achieve a 7 %
improvement in uptake on the basis of similar previous
research. Studies testing targeted ‘psycho-educational’
invitations have achieved a 5.9 % higher uptake of colo-
rectal cancer screening (flexible sigmoidoscopy) in
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deprived areas [48] and an 11.8 % increase in FOBT par-
ticipation [49]. Also, a 7 % increase would deliver clinically
meaningful benefit if scaled to a national programme.
With 2000 patients split equally into two groups, statis-
tical power to carry out two-sided tests at the 5 % signifi-
cance threshold is 90 %.
Statistical analysis methods
Primary analysis
The researcher carrying out the analyses will be blinded
to group allocation. Un-blinding will occur after the pri-
mary data analysis is complete and has been checked
and verified by a second researcher. Chi square associa-
tions and multivariate logistic regression analyses will be
carried out to compare uptake between the intervention
and control groups. These analyses will take an
intention-to-treat approach, including all patients identi-
fied and randomised. Due to the nature of this study,
there should be no missing data for uptake.
Secondary analysis
Interaction terms will be used in regression models to
investigate if there are differences in demographic and
smoking-related predictors of uptake and if these are as-
sociated with invitation group. The demographic and
smoking-related characteristics of attenders from each
invitation group will also be compared with those of the
overall invited group to further test for any biases in up-
take and to elucidate figures which could be used to help
gauge uptake by the high risk in the event of a national
lung cancer screening programme.
Further analyses will be carried out to explore willing-
ness to be screened, uptake of LDCT scans and informed
decision-making outcomes (i.e. knowledge, decisional
conflict, decisional satisfaction) by invitation group. This
will function as a check that the intervention invitation
materials do not adversely affect the patients’ ability to
make an informed decision, given their low burden ap-
proach to information provision.
Ethical approval, research governance and trial
sponsorship
This study was approved by the City Road and Hampstead
NHS Research Ethics Committee (REC; reference: 15/LO/
1186) on the 29th July 2015. Site-specific approval for the
two hospital sites has been obtained via the Integrated Re-
search Application System (IRAS), along with the neces-
sary approvals from their Research and Development
Departments. Any planned modifications to the protocol
will be approved by the REC before they are adopted by
the study.
This study has been adopted onto the NHS trial port-
folio and is sponsored by University College London
(UCL). The Joint Research Office (for UCL, UCH and
the Royal Free) may carry out independent audits and
on-site monitoring of the trial at any time and without
notice; in adherence to UCL’s respective policies and the
Department of Health’s Research Governance Frame-
work for Health and Social Care.
Study management
This study is a collaborative effort, run by the Health Be-
haviour Research Centre (HBRC) and the Lungs for Liv-
ing (L4L) Research Centre. The trial management group
(TMG) is comprised of the Principal Investigator, aca-
demic and clinical collaborators, and key researchers,
who will together monitor trial conduct and progress.
Data management, patient confidentiality and the con-
duct of all clinical and trial personnel will adhere to the
full clinical trial protocol (version 2.0 or subsequent ap-
proved versions), Good Clinical Practice guidelines, es-
sential standard operating procedures, the NHS Code of
Confidentiality and the Data Protection Act (UCL Re-
cords Office registration number: Z6364106/2015/10/
34). Inputting of data will comply with information gov-
ernance legislation. An audit trail of documentation and
data collection will be kept to enable monitoring by the
research team and external regulatory bodies, and to
protect against unintentional or unauthorised modifica-
tion. Formal involvement of a Clinical Trials Unit (CTU)
was deemed unnecessary by the UCL Institute of Clin-
ical Trials and Methodology (ICTM) portal review
group.
A Trial Steering Group (TSG) comprised of independ-
ent expert and lay members will meet with key members
of the TMG to oversee this study and agree any amend-
ments to the protocol. There will be meetings at
six month intervals (approximately) throughout the trial
recruitment phase. An Independent Data Monitoring
Committee (IDMC) will review data on secondary clin-
ical outcomes and sub-studies (to be reported else-
where). There will be no interim review of the
behavioural data as the behavioural intervention tested
here poses minimal risk to patient safety.
Trial status
This study began recruiting in October and is expected
to recruit for 12 months.
Discussion
This study will test a novel, low-cost and targeted invita-
tion strategy for lung cancer screening, which aims to
improve engagement with a screening offer by the high
risk, especially low SES smokers. If shown to be effect-
ive, the materials and strategy could be translated for
use by local screening pilots and a national screening
programme were one to be implemented. The results
would act as proof of principle that grass-roots research
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investigating psychosocial barriers to uptake within the
local high risk community can effectively inform the de-
velopment of engaging materials. Results will also inform
the feasibility of inviting high risk patients to screening via
primary care and provide figures to help estimate likely
uptake of a screening programme. Findings from this
study will be written in accordance with the CONSORT
Statement [50], submitted for publication to relevant
peer-reviewed journals and presented at conferences. A
summary of results will provided to any participants who
request this.
Additional files
Additional file 1: Targeted information leaflet. (PDF 2.06 MB)
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